News & Events – Ysios Capital

20 Nov 2024

Ysios Capital ESG Report

Upcoming events

AI in Drug Discovery and Biomedicine
31 March 2025
Barcelona
Redefining Early Stage of Investment (RESI)
1 April 2025
Barcelona
Life Sciences Conference – Van Lanschot Kempen
2 - 3 April 2025
Amsterdam
Swisss Biotech Day
5 - 6 May 2025
Basel

Type:

Year:

19 Mar 2014

Ysios Capital begins fundraising for Ysios Biofund II

New fund to back disruptive life sciences companies in Europe and US.

11 Mar 2014

TiGenix Reports Full Year 2013 Financial Results

Leuven (BELGIUM) – March 11, 2014 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, gives an update of its business activities and announces financial results for the full year 2013.

04 Feb 2014

TiGenix reaches major cell therapy milestone with 1000th implant of ChondroCelect

Leuven (BELGIUM) – February 4, 2014 – TiGenix (NYSE Euronext: TIG), a leader in thefield of cell therapy, announced today that it reached a major milestone with the performance of the 1000th ChondroCelect implantation for cartilage repair in the knee.

28 Jan 2014

American Journal of Kidney Disease publishes review article of Alkaline Phosphatase

Bunnik, The Netherlands, 28 January 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that the American Journal of Kidney Disease has published an In Translation feature entitled: Alkaline phosphatase: a possible new treatment option for sepsis-associated acute kidney injury in critically ill patients.

24 Jan 2014

TiGenix to sell Dutch manufacturing facility to PharmaCell

Leuven (BELGIUM) – January 24, 2014 – TiGenix (NYSE Euronext: TIG), a leader in the field of cell therapy, announced today that it has signed an agreement for the sale of its stateof- the-art Dutch production facility to PharmaCell B.V for a total consideration of EUR 5.75 million.PharmaCell, a leading European-based contract manufacturing organization active in the area of cell therapy and regenerative medicine, is to acquire the shares of TiGenix’s wholly owned subsidiary TiGenix B.V., which holds the Dutch manufacturing facility.

22 Jan 2014

MedLumics Expands Management Team in Preparation for 2014 Launch of First Generation Diagnostic Imaging System for Dermatology

MADRID--(BUSINESS WIRE)--MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of Miguel Eslava to the new position of vice president and chief operating officer.

23 Dec 2013

TiGenix secures EUR 10 million in financing from Kreos Capital Company ends year in strong position to fully leverage leading cell therapy platform

Leuven (BELGIUM) – December 23, 2013 – TiGenix (Euronext Brussels: TIG) announced today that it has signed a structured debt financing agreement of up to EUR 10 million with Kreos Capital (Kreos), Europe's largest and leading provider of growth debt to high-growth companies.

22 Nov 2013

TiGenix completes EUR 12 million capital increase with strategic investor Grifols

Leuven, Belgium – November 22, 2013, 12.15 p.m. – TiGenix NV (Euronext Brussels: TIG) announced today the successful completion of the EUR 12 million capital increase announced on November 20, 2013.

20 Nov 2013

TiGenix Raises EUR 12 million via a Private Placement of New Ordinary Shares

Leuven, Belgium – November 20, 2013, 8.30 a.m.–TiGenix NV (Euronext Brussels: TIG) today announces that on November 19, 2013, after the market closed, it has raised EUR 12 million through a private placement of 34.188.034 new ordinary shares with Gri- Cel S.A., a fully-owned subsidiary of global healthcare company Grifols S.A., at an issue price of EUR 0.351 per new share.

08 Nov 2013

AM-Pharma presents positive data from recAP preclinical study at ASN meeting

Bunnik, The Netherlands; Atlanta, GA, 8 November 2013. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today presents preclinical data on its drug candidate recAP in an Acute Kidney Injury (AKI) setting, at the American Society of Nephrology (ASN) meeting Kidney Week in Atlanta, GA, USA.